Gavin Samuels, Quark Pharmaceutical’s vice president of business development, has recently left the company.
A Quark spokeswoman said that Samuels left for “personal reasons” and that a search for a replacement is ongoing.
Exiqon announced that it has appointed Cynthia French as its CSO and Erik Holmlin as its chief commercial officer.
French will be responsible development for Exiqon’s research and diagnostic products. She previously served as vice president of Affymetrix’s clinical services laboratory. Prior to this, she was vice president and CSO at Specialty Laboratories. She holds a PhD and MBA from the University of California.
Holmlin joins Exiqon from BD Diagnostics, where he held various executive positions. He was also a co-founder of GeneOhm, which was acquired by BD Biosciences. He holds a PhD from the California Institute of Technology and an MBA from the University of California, Berkeley.
Silence Therapeutics said this week that it has appointed Annette Clancy and Jerry Randell as non-executive directors.
Additionally, Iain Rugheimer has resigned as a company director.
Clancy currently leads GlaxoSmithKline’s transactions and alliances team, a position from which she will retire at the end of 2008, while Randell is CFO of Sinclair Pharmaceuticals.
Rugheimer has been on Silence’s board of directors since 1995.
Thermo Fisher Scientific said that William Parrett has been elected to its board of directors.
Parrett was most recently Global CEO of Deloitte Touche Tohmatsu.